Currently, there are 293.59M common shares owned by the public and among those 286.53M shares have been available to trade.
The company’s stock has a 5-day price change of 0.42% and -6.92% over the past three months. FOLD shares are trading -16.56% year to date (YTD), with the 12-month market performance up to 5.34% higher. It has a 12-month low price of $9.70 and touched a high of $14.57 over the same period. FOLD has an average intraday trading volume of 3.24 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.21%, -8.25%, and -4.46% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Amicus Therapeutics Inc (NASDAQ: FOLD) shares accounts for 106.62% of the company’s 293.59M shares outstanding.
It has a market capitalization of $3.50B and a beta (3y monthly) value of 0.76. The earnings-per-share (ttm) stands at -$0.52. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.21% over the week and 3.85% over the month.
Analysts forecast that Amicus Therapeutics Inc (FOLD) will achieve an EPS of -$0.06 for the current quarter, -$0.02 for the next quarter and $0.4 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.08 while analysts give the company a high EPS estimate of -$0.03. Comparatively, EPS for the current quarter was -$0.18 a year ago. Earnings per share for the fiscal year are expected to increase by 100.97%, and 7948.83% over the next financial year.
Looking at the support for the FOLD, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on December 19, 2023, with the firm’s price target at $15-$20. Morgan Stanley coverage for the Amicus Therapeutics Inc (FOLD) stock in a research note released on September 09, 2022 offered a Equal-Weight rating with a price target of $14. Goldman was of a view on April 13, 2022 that the stock is Neutral, while SVB Leerink gave the stock Outperform rating on January 14, 2022, issuing a price target of $12- $16. Stifel on their part issued Buy rating on November 15, 2021.
